Table 1.
Baseline patient characteristics in 935 patients under going re-TUR
| Age, years | |
| <70, n (%) | 549 (58.7) |
| ≥70, n (%) | 386 (41.3) |
| Median (interquartile range) | 67 (59–74) |
| Sex | |
| Male | 756 (80.9) |
| Female | 179 (19.1) |
| Tumour status | |
| Primary T1G3 | 848 (90.7) |
| Recurrent after non T1G3 | 87 (9.3) |
| Previous intravesical chemotherapy | |
| No | 895 (95.8) |
| Yes | 40 (4.2) |
| Muscle in primary TUR specimen | |
| No | 276 (29.5) |
| Yes | 624 (66.8) |
| Missing/unknown | 35 (3.7) |
| Tumour grade | |
| WHO 1973 G3 | 442 (47.2) |
| WHO 2004 HG | 799 (85.4) |
| G3 and/or HG | 935 (100) |
| Tumour focality | |
| Solitary | 225 (24.1) |
| Multiple | 687 (73.5) |
| Missing/unknown | 23 (2.4) |
| Largest tumour diameter (cm) | |
| <3 | 257 (27.5) |
| ≥3 | 191 (20.4) |
| Missing/unknown | 487 (51.2) |
| Concomitant CIS | |
| No | 694 (74.2) |
| Yes | 241 (25.8) |
| Invasion of prostatic urethra | |
| No | 401 (42.9) |
| Yes, without stromal invasion | 18 (1.9) |
| Yes, with stromal invasion | 3 (0.3) |
| Missing/unknown | 513 (54.9) |
| Pathology at re-staging TUR* | |
| No residual tumour | 267 (28.6) |
| Ta | 378 (40.4) |
| T1 | 289 (30.9) |
| CIS | NA* |
| Missing/unknown | 1 (0.1) |
| Maintenance BCG | |
| No | 624 (66.8) |
| Yes | 311 (33.2) |
*
Separate information on CIS at re-TUR was not available